Insmed (INSM) Reports Q3 Earnings: What Key Metrics Have to Say

Core Insights - Insmed reported $93.43 million in revenue for Q3 2024, marking an 18.2% year-over-year increase, with an EPS of -$1.27 compared to -$1.10 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $93.31 million by 0.12%, while the EPS fell short of the consensus estimate of -$1.19 by 6.72% [1] Revenue Breakdown - Revenue from Japan was $20.98 million, below the estimated $24.10 million, but showed a year-over-year increase of 30.9% [3] - Revenue from Europe and the rest of the world reached $5.57 million, slightly above the $5.45 million estimate, reflecting a 45.3% year-over-year growth [3] - U.S. revenue was $66.87 million, surpassing the average estimate of $64.70 million, with a year-over-year increase of 13% [3] Stock Performance - Insmed's shares have declined by 3.7% over the past month, contrasting with a 1% increase in the Zacks S&P 500 composite [4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [4]